Case report: Anlotinib plus oral etoposide: a potential salvage therapy based on insights from EGFR-TKI-resistant SCLC transformation PDX and clinical settings
{{output}}
Small cell lung cancer (SCLC) transformation is one of the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with lung adenocarcinoma (LUAD). Platinum-etoposide chemotherapy is the most common ... ...
